NASDAQ:AMPH - Amphastar Pharmaceuticals Stock Price, Price Target & More

$19.56 -0.04 (-0.20 %)

(As of 04/19/2018 08:00 AM ET)

Previous Close$19.60

Today's Range$19.52 - $19.94

52-Week Range$13.15 - $20.45

Volume119,800 shs

Average Volume194,109 shs

Market Capitalization$908.47 million

P/E Ratio63.23

Dividend YieldN/A

Beta1.42

About Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

Receive AMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:AMPH

CUSIPN/A

Webwww.amphastar.com

Phone909-980-9484

Debt

Debt-to-Equity Ratio0.12%

Current Ratio2.79%

Quick Ratio1.85%

Price-To-Earnings

Trailing P/E Ratio63.23

Forward P/E Ratio31.05

P/E Growth1.39

Sales & Book Value

Annual Sales$240.18 million

Price / Sales3.77

Cash Flow$0.7299 per share

Price / Cash26.80

Book Value$7.34 per share

Price / Book2.66

Profitability

EPS (Most Recent Fiscal Year)$0.38

Net Income$4.50 million

Net Margins1.88%

Return on Equity4.56%

Return on Assets3.41%

Miscellaneous

Employees1,644

Outstanding Shares46,350,000

How to Become a New Pot Stock Millionaire

Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

How will Amphastar Pharmaceuticals' stock buyback program work?

Amphastar Pharmaceuticals announced that its board has authorized a share buyback program on Thursday, August 10th 2017, which permits the company to buyback $20,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's board believes its shares are undervalued.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) posted its earnings results on Monday, March, 12th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.07 by $0.03. The firm had revenue of $60.40 million for the quarter, compared to analysts' expectations of $60.62 million. Amphastar Pharmaceuticals had a net margin of 1.88% and a return on equity of 4.56%. The firm's revenue was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.01 EPS. View Amphastar Pharmaceuticals' Earnings History.

What price target have analysts set for AMPH?

6 Wall Street analysts have issued 1-year price targets for Amphastar Pharmaceuticals' shares. Their forecasts range from $18.00 to $26.00. On average, they expect Amphastar Pharmaceuticals' share price to reach $21.20 in the next year. View Analyst Ratings for Amphastar Pharmaceuticals.

Who are some of Amphastar Pharmaceuticals' key competitors?

Some companies that are related to Amphastar Pharmaceuticals include MyoKardia (MYOK), Arena Pharmaceuticals (ARNA), Phibro Animal Health (PAHC), OPKO Health (OPK), Enanta Pharmaceuticals (ENTA), Prestige Brands (PBH), Madrigal Pharmaceuticals (MDGL), Xencor (XNCR), Innoviva (INVA), Akcea Therapeutics (AKCA), Radius Health (RDUS), Prothena (PRTA), Impax Laboratories (IPXL), Zogenix (ZGNX), Pacira Pharmaceuticals (PCRX), ImmunoGen (IMGN), Immuron (IMRN) and Myovant Sciences (MYOV).

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the folowing people:

Mary Ziping Luo Ph.D., Chief Operating Officer, Chief Scientist and Chairman of the Board (Age 67)
Jason B. Shandell J.D., President, General Counsel, Director (Age 43)
Jack Yongfeng Zhang Ph.D., Chief Executive Officer, Chief Scientific Officer, Director (Age 70)
William J. Peters, Chief Financial Officer, Senior Vice President, Treasurer and President of Armstrong Pharmaceuticals, Inc. (Age 49)
Diane G. Gerst, Executive Vice President - Quality Assurance and Regulatory Affairs and President of Amphastar Nanjing Pharmaceuticals Inc (Age 57)
Rong Zhou, Executive Vice President - Production Center and President of Armstrong Pharmaceuticals, Inc. (Age 58)
Michael A. Zasloff M.D. Ph.D., Lead Independent Director (Age 71)
Richard Koo CPA, Independent Director (Age 76)
Howard S. Lee Ph.D., Independent Director (Age 54)
Floyd F. Petersen, Independent Director (Age 73)

Has Amphastar Pharmaceuticals been receiving favorable news coverage?

News stories about AMPH stock have been trending very positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amphastar Pharmaceuticals earned a news impact score of 0.53 on Accern's scale. They also assigned press coverage about the company an impact score of 45.22 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $19.56.

How big of a company is Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals has a market capitalization of $908.47 million and generates $240.18 million in revenue each year. The company earns $4.50 million in net income (profit) each year or $0.38 on an earnings per share basis. Amphastar Pharmaceuticals employs 1,644 workers across the globe.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]

MarketBeat Community Rating for Amphastar Pharmaceuticals (AMPH)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		198 (Vote Outperform)
Underperform Votes:		153 (Vote Underperform)
Total Votes:		351

MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

6 Wall Street analysts have issued ratings and price targets for Amphastar Pharmaceuticals in the last 12 months. Their average twelve-month price target is $21.20, suggesting that the stock has a possible upside of 8.38%. The high price target for AMPH is $26.00 and the low price target for AMPH is $18.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.67	2.67	2.67	2.83
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$21.20	$21.20	$19.20	$20.1667
Price Target Upside:	8.38% upside	6.75% upside	1.99% downside	15.37% upside

Amphastar Pharmaceuticals (NASDAQ:AMPH) Consensus Price Target History

Price Target History for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ:AMPH) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/21/2018	Wells Fargo	Reiterated Rating	Buy		Medium
3/13/2018	BMO Capital Markets	Reiterated Rating	Market Perform -> Market Perform	$17.00 -> $19.00	High
3/13/2018	Needham & Company LLC	Reiterated Rating	Buy -> Buy	$23.00 -> $24.00	High
1/30/2018	Piper Jaffray	Reiterated Rating	Buy	$26.00	Medium
11/9/2017	Raymond James	Downgrade	Outperform -> Market Perform	$18.00	N/A
10/29/2017	Jefferies Group	Set Price Target	Buy	$19.00	N/A

(Data available from 4/19/2016 forward)

Amphastar Pharmaceuticals (NASDAQ:AMPH) Earnings History and Estimates Chart

Earnings by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ:AMPH) Earnings Estimates

2018 EPS Consensus Estimate: $0.65

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	$0.11	$0.11	$0.11
Q2 2018	1	$0.11	$0.11	$0.11
Q3 2018	1	$0.13	$0.13	$0.13
Q4 2018	1	$0.30	$0.30	$0.30

Amphastar Pharmaceuticals (NASDAQ AMPH) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
3/12/2018	Q4 2017	$0.07	$0.10	$60.62 million	$60.40 million	View	Listen
11/8/2017	Q3 2017	$0.02	$0.07	$57.23 million	$57.90 million	View	N/A
8/9/2017	Q2 2017	$0.06	$0.11	$63.40 million	$65.20 million	View	Listen
5/8/2017	Q1 2017	$0.06	$0.03	$63.74 million	$56.67 million	View	Listen
3/13/2017	Q4 2016	($0.01)	$0.01	$55.78 million	$63.54 million	View	N/A
11/8/2016	Q3	$0.03	$0.14	$65.12 million	$64.20 million	View	Listen
8/8/2016	Q2	$0.01	$0.23	$62.10 million	$68.00 million	View	N/A
5/9/2016	Q1	($0.03)	$0.12	$62.00 million	$59.40 million	View	N/A
3/14/2016	Q415	($0.04)	$0.19	$64.48 million	$76.90 million	View	N/A
11/12/2015	Q315	($0.20)	($0.01)	$19.49 million	$63.90 million	View	Listen
8/12/2015	Q215	($0.11)	($0.09)	$19.49 million	$53.85 million	View	Listen
5/13/2015	Q115	($0.17)	($0.01)	$45.87 million	$56.89 million	View	Listen
3/24/2015	Q414	($0.06)	($0.03)	$54.90 million	$55.90 million	View	N/A
11/12/2014	Q314	($0.11)	($0.11)	$45.89 million	$59.70 million	View	N/A
8/12/2014	Q2 2014	($0.11)	$0.02	$44.23 million	$49.00 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

Amphastar Pharmaceuticals (NASDAQ:AMPH) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Amphastar Pharmaceuticals (NASDAQ AMPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.10%
Institutional Ownership Percentage: 44.50%

Insider Trading History for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ AMPH) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/20/2018	Jason B Shandell	Insider	Sell	20,000	$19.43	$388,600.00	251,372
3/15/2018	Richard K Prins	Director	Sell	16,598	$19.90	$330,300.20	45,442
3/14/2018	Jason B Shandell	Insider	Sell	700	$20.45	$14,315.00
3/13/2018	William J Peters	CFO	Sell	19,801	$20.10	$398,000.10
1/26/2018	Jason B. Shandell	Insider	Sell	18,627	$19.42	$361,736.34
1/25/2018	Jason B. Shandell	General Counsel	Sell	8,661	$19.26	$166,810.86
12/19/2017	Diane G Gerst	EVP	Sell	523	$19.48	$10,188.04	30,164
12/14/2017	Stephen B Shohet	Director	Sell	7,866	$18.87	$148,431.42	31,982
12/12/2017	Diane G Gerst	EVP	Sell	523	$18.96	$9,916.08	30,687
12/7/2017	Stephen B Shohet	Director	Sell	7,862	$18.34	$144,189.08	31,978
12/1/2017	William J. Peters	CFO	Sell	6,226	$19.67	$122,465.42
11/30/2017	Stephen B Shohet	Director	Sell	7,862	$19.25	$151,343.50	31,978
11/28/2017	Diane G Gerst	EVP	Sell	523	$18.15	$9,492.45	31,210
11/22/2017	Stephen B Shohet	Director	Sell	7,862	$18.94	$148,906.28	31,978
11/21/2017	Diane G Gerst	EVP	Sell	523	$18.81	$9,837.63	31,733
11/16/2017	Stephen B Shohet	Director	Sell	7,862	$18.04	$141,830.48	31,978
11/15/2017	Diane G Gerst	EVP	Sell	523	$17.77	$9,293.71	32,256
11/9/2017	Stephen B Shohet	Director	Sell	7,862	$18.55	$145,840.10	31,978
11/7/2017	Diane G Gerst	EVP	Sell	523	$17.93	$9,377.39	32,779
11/2/2017	Stephen B Shohet	Director	Sell	7,862	$18.37	$144,424.94
10/26/2017	Stephen B Shohet	Director	Sell	7,862	$18.39	$144,582.18	31,978
10/24/2017	Diane G Gerst	EVP	Sell	523	$18.29	$9,565.67	33,302
10/19/2017	Stephen B Shohet	Director	Sell	7,862	$18.34	$144,189.08	31,978
10/17/2017	Diane G Gerst	EVP	Sell	523	$18.48	$9,665.04	33,825
10/13/2017	William J Peters	CFO	Sell	3,026	$18.56	$56,162.56
10/12/2017	Stephen B Shohet	Director	Sell	7,862	$18.73	$147,255.26
10/5/2017	Diane G Gerst	EVP	Sell	8,444	$18.87	$159,338.28
10/4/2017	Floyd F Petersen	Director	Sell	39,312	$18.59	$730,810.08
10/2/2017	Michael A Zasloff	Director	Sell	63,624	$18.18	$1,156,684.32	101,879
8/15/2017	Richard K Prins	Director	Sell	10,000	$14.81	$148,100.00	33,844
8/14/2017	Richard K Prins	Director	Sell	5,000	$14.80	$74,000.00	33,844
6/9/2017	Richard K Prins	Director	Sell	10,000	$17.07	$170,700.00	28,844
6/1/2017	Michael A Zasloff	Director	Sell	15,000	$17.01	$255,150.00	47,411
5/31/2017	Jason B Shandell	Director	Sell	11,482	$16.92	$194,275.44	241,342
5/11/2017	Richard K Prins	Director	Sell	7,500	$15.43	$115,725.00	30,500
1/3/2017	Floyd F Petersen	Director	Sell	400	$18.61	$7,444.00	58,717
12/15/2016	Diane G Gerst	EVP	Sell	2,940	$20.51	$60,299.40	26,195
12/5/2016	Rong Zhou	EVP	Sell	61	$20.70	$1,262.70	36,991
12/1/2016	Floyd F Petersen	Director	Sell	400	$20.26	$8,104.00	59,117
11/28/2016	Jason B Shandell	Insider	Sell	26,335	$20.48	$539,340.80	205,004
11/15/2016	Howard Lee	Director	Sell	37,994	$20.65	$784,576.10	134,527
10/3/2016	Floyd F Petersen	Director	Sell	400	$18.75	$7,500.00	59,917
9/26/2016	Jason B Shandell	Insider	Sell	56,996	$19.50	$1,111,422.00	259,957
9/20/2016	Jack Y Zhang	CEO	Sell	444,199	$21.03	$9,341,504.97	1,295,685
9/8/2016	Floyd F Petersen	Director	Sell	3,000	$19.05	$57,150.00	60,317
9/1/2016	Howard Lee	Director	Sell	10,381	$18.78	$194,955.18	125
8/22/2016	Jason B Shandell	General Counsel	Sell	10,000	$19.95	$199,500.00	212,961
8/19/2016	Diane G Gerst	EVP	Sell	24,046	$19.28	$463,606.88	39,031
8/18/2016	Richard K Prins	Director	Sell	3,086	$19.62	$60,547.32	26,000
8/17/2016	Jason B Shandell	Insider	Sell	5,987	$18.86	$112,914.82	202,961
8/16/2016	Stephen B Shohet	Director	Sell	48,375	$18.24	$882,360.00	28,653
8/15/2016	Michael A Zasloff	Director	Sell	48,375	$18.15	$878,006.25	42,792
8/12/2016	William J Peters	CFO	Sell	1,027	$18.19	$18,681.13	63,625
8/11/2016	Jason B Shandell	President	Sell	5,636	$18.01	$101,504.36	208,948
8/11/2016	Richard K Prins	Director	Sell	13,993	$18.03	$252,293.79	31,681
7/18/2016	William J Peters	CFO	Sell	2,297	$17.76	$40,794.72	64,652
6/15/2016	Rong Zhou	EVP	Sell	1,551	$15.85	$24,583.35	37,137
6/13/2016	Richard K Prins	Director	Sell	7,500	$15.94	$119,550.00	29,086
6/9/2016	Jason B Shandell	President	Sell	9,904	$16.43	$162,722.72	216,610
6/2/2016	William J Peters	CFO	Sell	2,297	$16.00	$36,752.00	66,949
5/25/2016	Jason B Shandell	President	Sell	1,074	$15.60	$16,754.40	226,514
5/18/2016	Diane G Gerst	EVP	Sell	1,427	$13.97	$19,935.19	28,649
5/17/2016	Richard K Prins	Director	Sell	3,200	$13.56	$43,392.00	23,000
4/19/2016	Diane G Gerst	EVP	Sell	21,244	$12.89	$273,835.16	39,713
4/18/2016	Diane G Gerst	EVP	Sell	15,637	$12.83	$200,622.71	39,713
3/17/2016	Richard K Prins	Director	Sell	2,400	$11.25	$27,000.00	26,200
12/17/2015	Stephen B. Shohet	Director	Sell	30,770	$14.19	$436,626.30	12,186
12/16/2015	Howard Lee	Director	Sell	38,462	$14.34	$551,545.08	109,901
12/16/2015	Rong Zhou	EVP	Sell	772	$14.29	$11,031.88	25,460
12/11/2015	Jack Y Zhang	CEO	Sell	63,300	$14.25	$902,025.00	920,117
12/8/2015	Jack Y Zhang	CEO	Sell	68,117	$14.71	$1,002,001.07	920,117
12/3/2015	Jack Y Zhang	CEO	Sell	38,583	$15.45	$596,107.35	920,117
8/18/2015	Richard K Prins	Director	Sell	9,100	$14.66	$133,406.00
8/17/2015	Richard K. Prins	Director	Sell	5,400	$14.70	$79,380.00	35,722
7/17/2015	Michael A Zasloff	Director	Sell	7,692	$17.41	$133,917.72
6/17/2015	Rong Zhou	EVP	Sell	1,000	$16.48	$16,480.00
6/15/2015	Jack Y Zhang	CEO	Sell	45,382	$16.29	$739,272.78
6/12/2015	Jack Y Zhang	CEO	Sell	160,495	$16.23	$2,604,833.85
6/9/2015	Jack Y Zhang	CEO	Sell	193,758	$16.43	$3,183,443.94
5/22/2015	Richard K Prins	Director	Sell	29,452	$14.77	$435,006.04
5/19/2015	Richard K Prins	Director	Sell	3,000	$14.94	$44,820.00
4/9/2015	Marilyn J Purchase	VP	Sell	28,000	$15.79	$442,120.00
4/8/2015	Diane G Gerst	SVP	Sell	10,000	$15.79	$157,900.00
8/25/2014	Howard Lee	Director	Buy	6,000	$10.84	$65,040.00
8/19/2014	Michael A Zasloff	Director	Buy	3,500	$10.00	$35,000.00
8/18/2014	Richard K Prins	Director	Buy	4,000	$10.02	$40,080.00
8/15/2014	Floyd F Petersen	Director	Buy	3,200	$10.35	$33,120.00

(Data available from 1/1/2013 forward)

Amphastar Pharmaceuticals (NASDAQ AMPH) News Headlines

Source:

Date	Headline
	Amphastar Pharmaceuticals Inc (AMPH) Expected to Post Quarterly Sales of $63.15 Million www.americanbankingnews.com - April 17 at 4:00 AM
	Amphastar Pharmaceuticals Inc (AMPH) Expected to Announce Earnings of $0.09 Per Share www.americanbankingnews.com - April 15 at 11:15 AM
	Amphastar Pharmaceuticals Inc (AMPH) Receives Consensus Recommendation of "Hold" from Analysts www.americanbankingnews.com - April 4 at 5:52 PM
	What Is Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) Share Price Doing? finance.yahoo.com - April 4 at 5:17 PM
	Amphastar Pharmaceuticals (AMPH) Downgraded by Raymond James Financial to "Market Perform" www.americanbankingnews.com - March 31 at 6:34 PM
	Amphastar Pharmaceuticals Inc (AMPH) Expected to Announce Quarterly Sales of $63.15 Million www.americanbankingnews.com - March 31 at 3:00 AM
	Amphastar Pharmaceuticals (AMPH) Downgraded by BidaskClub www.americanbankingnews.com - March 30 at 9:17 AM
	Amphastar Pharmaceuticals (AMPH) Presents At Needham and Company 17th Annual Healthcare Conference - Slideshow seekingalpha.com - March 29 at 4:16 PM
	Analysts Expect Amphastar Pharmaceuticals Inc (AMPH) to Post $0.09 EPS www.americanbankingnews.com - March 29 at 1:52 PM
	Is Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) A Sell At Its Current PE Ratio? finance.yahoo.com - March 28 at 9:57 AM
	Amphastar Pharmaceuticals to Present at the Needham's 17th Annual Healthcare Conference globenewswire.com - March 26 at 4:09 PM
	Amphastar Pharmaceuticals (AMPH) Earns Buy Rating from Piper Jaffray www.americanbankingnews.com - March 26 at 1:26 PM
	Amphastar Pharmaceuticals to Present at the Needham’s 17th Annual Healthcare Conference finance.yahoo.com - March 26 at 10:11 AM
	Amphastar Pharma (AMPH) Reports Favorable Final Judgement in Patent Litigation Against Momenta Pharmaceuticals Inc. and Sandoz Inc. www.streetinsider.com - March 23 at 9:39 AM
	Amphastar Pharmaceuticals' (AMPH) Buy Rating Reaffirmed at Wells Fargo www.americanbankingnews.com - March 22 at 10:54 PM
	Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. - GlobeNewswire (press release) globenewswire.com - March 22 at 4:11 PM
	Head to Head Comparison: Pernix Therapeutics (PTX) vs. Amphastar Pharmaceuticals (AMPH) www.americanbankingnews.com - March 21 at 1:20 PM
	Amphastar Pharma (AMPH) Reports Favorable Final Judgement in Patent Litigation Against Momenta Pharmaceuticals ... - StreetInsider.com www.streetinsider.com - March 21 at 10:55 AM
	Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. - Nasdaq www.nasdaq.com - March 21 at 10:55 AM
	Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. finance.yahoo.com - March 21 at 10:54 AM
	Jason B. Shandell Sells 20,000 Shares of Amphastar Pharmaceuticals Inc (AMPH) Stock www.americanbankingnews.com - March 20 at 10:14 PM
	Amphastar Pharmaceuticals (AMPH) Raised to Hold at BidaskClub www.americanbankingnews.com - March 18 at 7:10 PM
	Richard K. Prins Sells 16,598 Shares of Amphastar Pharmaceuticals Inc (AMPH) Stock www.americanbankingnews.com - March 16 at 7:52 PM
	Aquinox Pharmaceuticals (AQXP) and Amphastar Pharmaceuticals (AMPH) Head-To-Head Comparison www.americanbankingnews.com - March 16 at 1:06 PM
	Jefferies Group Weighs in on Amphastar Pharmaceuticals Inc's FY2018 Earnings (AMPH) www.americanbankingnews.com - March 16 at 10:48 AM
	Amphastar Pharmaceuticals Inc (AMPH) Insider Jason B. Shandell Sells 700 Shares www.americanbankingnews.com - March 15 at 8:30 PM
	William J. Peters Sells 19,801 Shares of Amphastar Pharmaceuticals Inc (AMPH) Stock www.americanbankingnews.com - March 15 at 7:46 PM
	Research Analysts Offer Predictions for Amphastar Pharmaceuticals Inc's Q1 2018 Earnings (AMPH) www.americanbankingnews.com - March 15 at 7:37 AM
	Amphastar Pharmaceuticals (AMPH) Q4 2017 Earnings Conference Call Transcript finance.yahoo.com - March 14 at 5:25 PM
	Amphastar Pharmaceuticals Inc (AMPH) Expected to Announce Quarterly Sales of $67.30 Million www.americanbankingnews.com - March 14 at 12:12 PM
	Amphastar Pharmaceuticals (AMPH) Lowered to "Hold" at Zacks Investment Research www.americanbankingnews.com - March 13 at 4:35 PM
	Amphastar Pharmaceuticals (AMPH) PT Raised to $19.00 at BMO Capital Markets www.americanbankingnews.com - March 13 at 3:55 PM
	Amphastar Pharmaceuticals (AMPH) Price Target Raised to $24.00 www.americanbankingnews.com - March 13 at 3:50 PM
	Amphastar Pharmaceuticals' (AMPH) CEO Yongfeng Zhang on Q4 2017 Results - Earnings Call Transcript seekingalpha.com - March 13 at 10:04 AM
	Amphastar Pharmaceuticals (AMPH) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS www.americanbankingnews.com - March 12 at 9:10 PM
	Amphastar Pharmaceutical Q4 Earnings Preview finance.yahoo.com - March 12 at 5:18 PM
	Amphastar beats Street 4Q forecasts finance.yahoo.com - March 12 at 5:18 PM
	Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Fiscal Year Ended December 31, 2017 finance.yahoo.com - March 12 at 5:18 PM
	Amphastar Pharmaceuticals Inc (AMPH) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - March 10 at 6:12 PM
	Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 12, 2018 finance.yahoo.com - March 5 at 4:48 PM
	Amphastar Pharmaceuticals (AMPH) Cut to Sell at BidaskClub www.americanbankingnews.com - March 3 at 6:10 PM
	Should You Be Concerned About Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) -98.57% Earnings Decline? finance.yahoo.com - March 2 at 9:34 AM
	Mallinckrodt PLC (MNK) Jumps: Stock Rises 15.3% finance.yahoo.com - February 28 at 9:37 AM
	How Did Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) 0.09% ROE Fare Against The Industry? finance.yahoo.com - February 22 at 9:29 AM
	Key Factors to Influence Penumbra's (PEN) Earnings in Q4 finance.yahoo.com - February 21 at 9:53 AM
	Amphastar Pharmaceuticals Inc (AMPH) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - February 13 at 5:36 PM
	Amphastar Pharmaceuticals (AMPH) Rating Increased to Hold at BidaskClub www.americanbankingnews.com - February 10 at 1:06 PM
	$60.11 Million in Sales Expected for Amphastar Pharmaceuticals Inc (AMPH) This Quarter www.americanbankingnews.com - February 8 at 6:02 AM
	What's in Store for Cardinal Health (CAH) in Q2 Earnings? finance.yahoo.com - January 30 at 9:21 AM
	Insider Selling: Amphastar Pharmaceuticals Inc (AMPH) General Counsel Sells 8,661 Shares of Stock www.americanbankingnews.com - January 27 at 12:12 AM

Amphastar Pharmaceuticals (NASDAQ:AMPH) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Amphastar Pharmaceuticals (NASDAQ:AMPH) Income Statement, Balance Sheet and Cash Flow Statement

Amphastar Pharmaceuticals (NASDAQ AMPH) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff